Table 1.
Absolute values [× 109/L] and SD of T-cell subsets after 6, 12, and 24 months of DMF treatment compared to baseline values in a longitudinal analysis of a smaller cohort of patients.
|
Baseline (n = 13) |
6 months (n = 13) |
12 months (n = 13) |
24 months (n = 13) |
|
|---|---|---|---|---|
| CD4+ T | 623.2 (212.0) |
506 (245.4) p = 0.127 |
522 (282.0) p = 0.147 |
503.2 (282.0) p = 0.080 |
| CD8+ T | 368.6 (337.3) |
237.5 (150.4) p = 0.020 |
150.7 (88.0) p = 0.002 |
196 (98.0) p = 0.006 |
| CD4+/CD8+ | 2. (0.7) |
2.4 (0.8) p = 0.240 |
3.8 (1.5) p = 0.001 |
2.7 (0.8) p = 0.026 |
| Th-1 | 69.8 (25.4) |
102.6 (62.4) p = 0.084 |
112.9 (61.5) p = 0.034 |
53.9 (58.9) p = 0.176 |
| Th-2 | 64.8 (36.2) |
78.5 (58.1) p = 0.685 |
89.1 (36.2) p = 0.060 |
38.5 (25.7) p = 0.056 |
| Th-17 | 97.5 (44.0) |
76.6 (27.3) p = 0.273 |
102.7 (37.6) p = 0.772 |
101.5 (52.5) p = 0.999 |
| T-reg | 14.8 (9.2) |
11.9 (11.5) p = 0.465 |
7.4 (4.8) p = 0.033 |
14.7 (7.4) p = 0.983 |
| NK cells |
% change 3 months |
% change 6 months |
% change 12 months |
% change 24 months |
| Baseline | 41.2 (84.8) n = 23, p = 0.346 |
18.9 (80.5) n = 29, p = 0.991 |
75.3 (108.0) n = 31, p = 0.035 |
85.9 (98.2) n = 26, p < 0.001 |
| 3 months | −1.9 (75.0) n = 22, p = 0.045 |
58.8 (98.2) n = 18, p = 0.112 |
50.4 (106.0) n = 14, p = 0.376 |
|
| 6 months | 122 (213.0) n = 21, p = 0.011 |
101 (200.0) n = 17, p = 0.245 |
||
| 12 months | 31.5 (110.0) n = 26, p = 0.300 |
NK cells absolute values at baseline and percentage change (SD) between different time-points during DMF therapy are also shown. p < 0.05 were considered statistically significant (bold font).